Numerous studies have investigated the selective application of new treatment modalities based on targeting tumor hypoxia (15,19), reporting that hypoxic markers, including HIF-1α, CA9 and VEGF, may be specific and favorable therapeutic targets. The gene discussed is VEGFA; the disease is neoplasm.